StreetInsider.com News Articles

Therma Bright Announces Expanded U.S. Orders for Venowave and Mobilizes Supply Chain for Upcoming Sales Volume

Tue, 23 Jun 2026 06:30:00 -0400

The Company Announces Shares for Debt Settlements

Toronto, Ontario--(Newsfile Corp. - June 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce continued sales momentum for its Venowave mobile compression device in the United States, highlighted by additional follow-on orders from Horizon Health USA ("Horizon") and from Gen-X Med.

Building on the rapid deployment of previous shipments, Horizon Health USA has placed a new order for 100 Venowave units. This brings Horizon's positive order history to a total of 300 units

Therma Bright Announces Expanded U.S. Orders for Venowave and Mobilizes Supply Chain for Upcoming Sales Volume

Tue, 23 Jun 2026 06:30:00 -0400

The Company Announces Shares for Debt Settlements

Building on the rapid deployment of previous shipments, Horizon Health USA has placed a new order for 100 Venowave units. This brings Horizon's positive order history to a total of 300 units

Therma Bright receives second 100-unit order from Horizon Health

Tue, 05 May 2026 06:32:32 -0400

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) announced that Horizon Health has purchased an additional 100 Venowave units, marking the second commercial order from the distributor.

The follow-on purchase comes after Horizon Health's initial 100-unit shipment was delivered in late March 2026. The medical device company said the repeat order follows deployment and clinical use of the first batch of units.

"Seeing Horizon Health return so quickly for a second order validates our belief that Venowave is a superior solution for vascular patients," said Rob Fia, CEO of Therma Bright.

Venowave is a battery-operated compression device worn on the calf designed

Therma Bright Announces Follow-On Order from Horizon Health as Venowave(TM) Gains Traction in U.S. Vascular Markets

Tue, 05 May 2026 06:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce that Horizon Health ("Horizon") has purchased an additional 100 Venowave™ units. This second commercial order follows the rapid deployment and clinical success of the initial 100-unit shipment delivered to Horizon in late March 2026.

The decision by Horizon Health to double its initial commitment underscores the strong demand for the Venowave™ mobile compression device within Horizon's extensive vascular patient population. By leveraging Horizon's established distribution

Therma Bright Announces Follow-On Order from Horizon Health as Venowave(TM) Gains Traction in U.S. Vascular Markets

Tue, 05 May 2026 06:30:00 -0400

Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually

Tue, 31 Mar 2026 06:30:00 -0400

Therma Bright Builds on Revenue Progress with Initial 100-Unit Venowave™ Order; Signals Expansion into Cosmetic Wellness Market

Toronto, Ontario--(Newsfile Corp. - March 31, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces it has secured a strategic commercial order for an initial 100 Venowave™ units from Horizon Health ("Horizon").

This milestone order follows a successful 2025 proof-of-concept phase, during which Therma Bright optimized its delivery and support protocols for the U.S. market. Horizon Health, headquartered in Baltimore, Maryland, is an

Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually

Tue, 31 Mar 2026 06:30:00 -0400

Therma Bright Builds on Revenue Progress with Initial 100-Unit Venowave™ Order; Signals Expansion into Cosmetic Wellness Market

Therma Bright Grants Stock Options

Fri, 13 Mar 2026 17:54:00 -0400

Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces that it has granted incentive stock options to its directors, officers and certain consultants of the Company to purchase up to an aggregate of 2,850,000 common shares of the Company pursuant to its 10% rolling stock option plan. All options are fully vested and are exercisable for a period of 2 years at a price of $0.07 per share. The options and any

Therma Bright Grants Stock Options

Fri, 13 Mar 2026 17:54:00 -0400

Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial

Tue, 10 Feb 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a major clinical milestone for its portfolio company, Inretio. The medical device innovator has successfully completed the first cohort of the First-in-Human (FIH) study for the PREVA™ Neuro-Thrombectomy System, moving the company rapidly toward a planned U.S. pivotal trial.

Clinical & Regulatory Acceleration: Following the positive review from the Data Safety Monitoring Board (DSMB), Inretio has received approval to continue patient enrollment. This

Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial

Tue, 10 Feb 2026 07:00:00 -0400

Clinical & Regulatory Acceleration: Following the positive review from the Data Safety Monitoring Board (DSMB), Inretio has received approval to continue patient enrollment. This

Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med

Tue, 20 Jan 2026 06:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce it has received a follow-on order for an additional 200 Venowave™ VW5 units from its Texas-based distribution partner, Gen-X Med.

This latest transaction marks the expansion of the relationship between the two companies, following the successful initial integration of the Venowave™ system into Gen-X Med's specialized healthcare network. The units are destined for use by top-tier orthopedic surgeons, specifically targeting post-surgical

Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med

Tue, 20 Jan 2026 06:30:00 -0400

Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.

Thu, 18 Dec 2025 07:00:00 -0400

Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025

Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update on Investee company, InStatin.

InStatin, a biotechnology company developing inhaled statin therapies for respiratory diseases, today reported significant progress from June 2024 through December 2025, despite a challenging investment climate. The company has refined its clinical strategy, advanced its lead molecule, and expanded its leadership and advisory teams.

"Despite capital headwinds,

Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.

Thu, 18 Dec 2025 07:00:00 -0400

Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025

"Despite capital headwinds,

Therma Bright adds healthcare veteran Raimondo to board

Fri, 10 Oct 2025 06:32:13 -0400

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) appointed Michael Raimondo to its board of directors, the medical device technology company announced. Raimondo previously served on the company's advisory board since August 2024.

Raimondo brings three decades of healthcare industry experience, including senior leadership positions at Abbott where he focused on commercial strategy and business development. The company stated he has led negotiations resulting in over $500 million in sales contracts during his career.

He currently serves as commercial lead for Delphine Diagnostics in New Jersey and as managing partner at The Potentia Group, which provides negotiations training and sales leadership

Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors

Fri, 10 Oct 2025 06:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 10, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the appointment of Michael Raimondo, a 30-year veteran in sales and operations in the healthcare industry to its Board of Directors. Michael was part of Therma's advisory Board, previously announced on August 13, 2024.

Mr. Raimondo is a distinguished executive and strategist known for his extensive commercial leadership experience in the healthcare and business services sectors across the USA. Mr. Raimondo specializes in

Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors

Fri, 10 Oct 2025 06:30:00 -0400

Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) Sales

Wed, 24 Sep 2025 06:30:00 -0400

Initial 200-Unit Sale previously announced on April 24, 2025, Targeted Specialized Knee Surgeons in U.S. Healthcare Network

Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a strategic partnership with Gen-X Med, a specialized medical product distributor based in Arlington, Texas. The partnership was hatched after the initial sale of 200 Venowave™ VW5 units that targeted patients that had undergone specialized knee surgeries by trained surgeons with expertise in the procedure.

Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) Sales

Wed, 24 Sep 2025 06:30:00 -0400

Initial 200-Unit Sale previously announced on April 24, 2025, Targeted Specialized Knee Surgeons in U.S. Healthcare Network

Therma Bright Proposes to Amend Certain Warrants

Thu, 28 Aug 2025 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 28, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company") announces that subject to the approval of the TSX Venture Exchange (the "TSXV"), the Company intends to amend the exercise price of an aggregate of 6,250,000 outstanding post-consolidation common share purchase warrants of the Company (the "Warrants") that were issued as part of the Company's private placement ("Private Placement") that closed in two tranches on June 10, 2024 and June 20, 2024. The Warrants post-consolidation original exercise price is $0.80 per share until they expire on June

Therma Bright Proposes to Amend Certain Warrants

Thu, 28 Aug 2025 07:00:00 -0400

Therma Bright Announces Share Consolidation

Thu, 03 Jul 2025 06:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 3, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company") announces, further to its news release dated June 11, 2025, that effective Tuesday, July 8, 2025, the Company will consolidate the common shares in the capital of the Company (the "Shares") on the basis of one (1) post-consolidation Share for every eight (8) pre-consolidation Shares (the "Consolidation"). The new CUSIP number will be 883426207 and the new ISIN number will be CA8834262070 for the post-Consolidation Shares.

The Company currently has 454,457,147 Shares issued and outstanding and there will

Therma Bright Announces Share Consolidation

Thu, 03 Jul 2025 06:30:00 -0400

The Company currently has 454,457,147 Shares issued and outstanding and there will

Therma Bright Inc. Announces Share Consolidation

Wed, 11 Jun 2025 06:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces, subject to the approval of the TSX Venture Exchange (the "TSXV"), that it will be undertaking a consolidation (the "Consolidation") of its common shares on the basis of eight (8) pre-Consolidation common shares for one (1) post-Consolidation common share. The Company expects that the Consolidation will provide the Company with increased flexibility in structuring and completing financings and potential business transactions.

No fractional common